Toyohara Jun, Okada Maki, Toramatsu Chie, Suzuki Kazutoshi, Irie Toshiaki
Department of Molecular Probes, Molecular Imaging Center, National Institute of Radiological Sciences, Chiba 263-8555, Japan.
Nucl Med Biol. 2008 Jan;35(1):67-74. doi: 10.1016/j.nucmedbio.2007.10.001.
This study reports on the radiosynthesis and feasibility studies of 4'-[methyl-(11)C]thiothymidine ([methyl-(11)C]S-dThd) as a tumor proliferation imaging agent. [Methyl-(11)C]S-dThd was synthesized by rapid methylation of corresponding 5-trimethylstannyl- or 5-tributylstannyl-precursor via a palladium-promoted Stille cross-coupling reaction with [(11)C]methyl iodide. The decay-corrected radiochemical yields of [methyl-(11)C]S-dThd synthesized by the corresponding 5-trimethylstannyl-precursor and 5-tributylstannyl-precursor based on [(11)C]CO(2) were 18.9% and 14.5%, respectively. The radiochemical purity of [methyl-(11)C]S-dThd was always greater than 99%. The specific activities of [methyl-(11)C]S-dThd synthesized by the corresponding 5-trimethylstannyl-precursor and 5-tributylstannyl-precursor were 47 GBq/mumol and 121 GBq/mumol, respectively, at the end of the synthesis. The total synthesis time was 30 min after the end of bombardment. The comparison between in vivo distribution of [methyl-(14)C]S-dThd and that of [methyl-(3)H]FLT showed that tracer uptake was comparable in nonproliferating tissues. In contrast, [methyl-(14)C]S-dThd showed significantly higher uptake in proliferating tissues than did [methyl-(3)H]FLT. [Methyl-(11)C]S-dThd uptake levels in five different tumor tissues were well correlated with the DNA synthesis levels determined by [2-(14)C]thymidine DNA incorporation. At 30 min after injection, plasma analysis found 95% of the activity in unmetabolized form. The microPET imaging of the C6 glioma xenograft showed significantly high uptake in the tumor and urinary bladder, followed by the intestine and marrow. Our results demonstrated that the tumor uptake of [methyl-(11)C]S-dThd was higher than that of [methyl-(3)H]FLT and was well correlated with the DNA synthesis level. Consequently, 4'-[methyl-(11)C]thiothymidine has promise for the imaging of tumor cell proliferation by positron emission tomography.
本研究报告了4'-[甲基-(11)C]硫代胸腺嘧啶核苷([甲基-(11)C]S-dThd)作为一种肿瘤增殖显像剂的放射性合成及可行性研究。[甲基-(11)C]S-dThd是通过相应的5-三甲基锡基或5-三丁基锡基前体与[11)C]甲基碘经钯促进的Stille交叉偶联反应快速甲基化合成的。基于[11)C]CO₂,由相应的5-三甲基锡基前体和5-三丁基锡基前体合成的[甲基-(11)C]S-dThd的衰变校正放射化学产率分别为18.9%和14.5%。[甲基-(11)C]S-dThd的放射化学纯度始终大于99%。在合成结束时,由相应的5-三甲基锡基前体和5-三丁基锡基前体合成的[甲基-(11)C]S-dThd的比活度分别为47 GBq/μmol和121 GBq/μmol。轰击结束后总合成时间为30分钟。[甲基-(14)C]S-dThd与[甲基-(3)H]FLT体内分布的比较表明,在非增殖组织中示踪剂摄取相当。相比之下,[甲基-(14)C]S-dThd在增殖组织中的摄取明显高于[甲基-(3)H]FLT。五种不同肿瘤组织中[甲基-(11)C]S-dThd的摄取水平与通过[2-(14)C]胸腺嘧啶核苷DNA掺入测定的DNA合成水平密切相关。注射后30分钟,血浆分析发现95%的活性以未代谢形式存在。C6胶质瘤异种移植瘤的microPET成像显示肿瘤和膀胱摄取明显增高,其次是肠道和骨髓。我们的结果表明,[甲基-(11)C]S-dThd的肿瘤摄取高于[甲基-(3)H]FLT,且与DNA合成水平密切相关。因此,4'-[甲基-(11)C]硫代胸腺嘧啶核苷有望用于正电子发射断层显像肿瘤细胞增殖。